Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) Director Robert Hershberg sold 30,664 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $24.40, for a total transaction of $748,201.60. Following the sale, the director directly owned 46,683 shares of the company’s stock, valued at approximately $1,139,065.20. This trade represents a 39.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Adaptive Biotechnologies Trading Down 0.2%
NASDAQ ADPT traded down $0.05 during mid-day trading on Thursday, hitting $25.44. The company’s stock had a trading volume of 1,966,087 shares, compared to its average volume of 2,336,118. Adaptive Biotechnologies Corporation has a 52-week low of $12.00 and a 52-week high of $26.16. The stock’s fifty day simple moving average is $21.75 and its two-hundred day simple moving average is $17.24. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The firm has a market capitalization of $4.06 billion, a P/E ratio of -62.05 and a beta of 2.08.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The business had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. During the same period last year, the firm earned ($0.17) earnings per share. The company’s quarterly revenue was up 21.5% on a year-over-year basis. Research analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.
Institutional Trading of Adaptive Biotechnologies
Analyst Upgrades and Downgrades
Several research firms recently weighed in on ADPT. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Guggenheim increased their price target on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Piper Sandler raised their price objective on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. TD Cowen boosted their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, JPMorgan Chase & Co. decreased their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and an average price target of $24.42.
Read Our Latest Analysis on Adaptive Biotechnologies
About Adaptive Biotechnologies
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Articles
- Five stocks we like better than Adaptive Biotechnologies
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
